Addex Therapeutics' Cash Dips Below CHF 1M Amid Widening Q1 Loss, Intensifying Going Concern Risk
ADXN is trading near its 52-week low of $5.41 (11% above the low).
Summary
Addex Therapeutics reported a Q1 2026 net loss of CHF 1.7 million, an increase from the prior year, and its cash and cash equivalents plummeted to CHF 0.9 million. This follows the company's 20-F filing on May 15th, which raised substantial doubt about its ability to continue as a going concern, and previous reports of critically low cash balances in April. A cash balance below CHF 1 million for a clinical-stage biotech with a $6.6 million market cap is extremely precarious, indicating severe liquidity issues and a high likelihood of imminent, highly dilutive financing or potential insolvency. The upcoming conference call today will likely provide more details on their cash runway and financing plans.
At the time of this announcement, ADXN was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6M. The 52-week trading range was $5.41 to $12.05. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.